Discussion about this post

User's avatar
Just steve's avatar

Huh? Maybe there is something to the old joke - My bald head is a solar panel for my brain. Seems like another layer of evidence the good old Sun, yet avoiding sunburns potentially feeds our bodies, health. Being as this has been vilified for so long and its only been in recent years old dogma has been allowed to be challenged somewhat, it may well be likely there is or are deeper layers of how the Sun understood properly is a building block for a long, productive life.

Summer Sun never fails to push the ache of winter out of the bones and joints. So many times it makes the world seem right no matter what may be going on.

Guillermou's avatar

Cancer is a chronic disease responsible for millions of deaths annually. Its multifaceted profile, with diverse types and anatomical locations, complicates treatment, which is often limited to surgery, radiotherapy, and chemotherapy. These treatments are frequently associated with increased tumor aggressiveness and recurrence, underscoring the urgent need for new, less invasive therapies. Recent studies suggest that blue light (BL; 450–470 nm) may offer antitumor and pro-apoptotic effects, making it a promising alternative for cancer treatment. However, its cellular and molecular mechanisms remain unclear. This qualitative systematic review, conducted according to the PRISMA guidelines, analyzed 37 in vitro and in vivo studies published between 2002 and 2024, retrieved from databases such as MEDLINE/PubMed, EMBASE, and LILACS, focusing on the effects of photobiomodulation (PBM) with blue light (450–470 nm) in preclinical cancer models. BL demonstrated antitumor potential by reducing cell viability, proliferation, migration, and invasion, as well as by increasing the production of reactive oxygen species (ROS) and inducing apoptosis. In animal models, BL also inhibited tumor growth and metastasis and improved survival. Despite these encouraging results, considerable methodological heterogeneity and insufficient information on dosimetric parameters compromise the reproducibility and comparability of results across studies. These findings highlight the therapeutic potential of BL in oncology and underscore the need for standardized protocols for its clinical application.

In summary, photobiomodulation (PBM) therapy can alleviate the side effects of cancer treatments, such as acute oral mucositis, radiation dermatitis, lymphedema, neuropathic pain, and radiation enteropathy, significantly improving the quality of life of cancer patients. Furthermore, a growing body of preclinical and clinical evidence indicates that photobiomodulation (PBM) not only mitigates adverse effects but can also inhibit cancer cell proliferation and induce apoptosis, suggesting its potential as a complementary tool in tumor treatment.

However, the current variability in treatment parameters and dosages remains a crucial challenge, as inconsistent results have been observed across different studies. This variability underscores the need for a more comprehensive understanding of the mechanisms underlying the effects of photobiomodulation (PBM). Future research should focus on several key areas. First, expanding clinical trials with larger cohorts and longer follow-up periods is essential to confirm the efficacy and safety of PBM therapy in diverse patient populations. Second, rigorous preclinical studies are needed to elucidate the cellular and molecular pathways affected by PBM, which could help identify the most effective treatment protocols. Third, efforts to standardize PBM parameters—including wavelength, dose, and treatment duration—are crucial to minimizing outcome variability and ensuring reproducibility across different clinical settings.

Overall, while PBM therapy represents a promising complementary approach to cancer treatment, its successful integration into conventional treatment regimens will depend on protocol standardization and a deeper mechanistic understanding of its effects.

ahttps://onlinelibrary.wiley.com/doi/full/10.1111/php.70025 (2025)

-- https://onlinelibrary.wiley.com/doi/full/10.1111/php.14107 (2025)

5 more comments...

No posts

Ready for more?